1.Assessment of Antioxidant and Phenolic Compound Concentrations as well as Xanthine Oxidase and Tyrosinase Inhibitory Properties of Different Extracts of Pleurotus citrinopileatus Fruiting Bodies.
Nuhu ALAM ; Ki Nam YOON ; Kyung Rim LEE ; Hye Young KIM ; Pyung Gyun SHIN ; Jong Chun CHEONG ; Young Bok YOO ; Mi Ja SHIM ; Min Woong LEE ; Tae Soo LEE
Mycobiology 2011;39(1):12-19
Cellular damage caused by reactive oxygen species has been implicated in several diseases, thus establishing a significant role for antioxidants in maintaining human health. Acetone, methanol, and hot water extracts of Pleurotus citrinopileatus were evaluated for their antioxidant activities against beta-carotene-linoleic acid and 1,1-diphenyl-2-picrylhydrazyl (DPPH) radicals, reducing power, ferrous ion-chelating abilities, and xanthine oxidase inhibitory activities. In addition, the tyrosinase inhibitory effects and phenolic compound contents of the extracts were also analyzed. Methanol and acetone extracts of P. citrinopileatus showed stronger inhibition of beta-carotene-linoleic acid compared to the hot water extract. Methanol extract (8 mg/mL) showed a significantly high reducing power of 2.92 compared to the other extracts. The hot water extract was more effective than the acetone and methanole extracts for scavenging DPPH radicals. The strongest chelating effect (92.72%) was obtained with 1.0 mg/mL of acetone extract. High performance liquid chromatography analysis detected eight phenolic compounds, including gallic acid, protocatechuic acid, chlorogenic acid, ferulic acid, naringenin, hesperetin, formononetin, and biochanin-A, in an acetonitrile and hydrochloric acid (5 : 1) solvent extract. Xanthine oxidase and tyrosinase inhibitory activities of the acetone, methanol, and hot water extracts increased with increasing concentration. This study suggests that fruiting bodies of P. citrinopileatus can potentially be used as a readily accessible source of natural antioxidants.
Acetone
;
Acetonitriles
;
Antioxidants
;
Biphenyl Compounds
;
Chlorogenic Acid
;
Chromatography, Liquid
;
Coumaric Acids
;
Flavanones
;
Fruit
;
Gallic Acid
;
Hesperidin
;
Humans
;
Hydrochloric Acid
;
Hydroxybenzoates
;
Isoflavones
;
Methanol
;
Monophenol Monooxygenase
;
Phenol
;
Picrates
;
Pleurotus
;
Reactive Oxygen Species
;
Water
;
Xanthine
;
Xanthine Oxidase
2.Appraisal of Antihyperlipidemic Activities of Lentinus lepideus in Hypercholesterolemic Rats.
Ki Nam YOON ; Jae Seong LEE ; Hye Young KIM ; Kyung Rim LEE ; Pyung Gyun SHIN ; Jong Chun CHEONG ; Young Bok YOO ; Nuhu ALAM ; Tai Moon HA ; Tae Soo LEE
Mycobiology 2011;39(4):283-289
The wild edible mushroom, Lentinus lepideus has recently been cultivated for commercial use in Korea. While the mushroom has been widely used for nutritional and medicinal purposes, the possible anti-hyperlipidemic action is unclear. The effects of dietary L. lepideus on plasma and feces biochemical and on the liver histological status were investigated in hypercholesterolemic rats. Six-wk-old female Sprague-Dawley albino rats were divided into three groups of 10 rats each. Biochemical and histological examinations were performed. A diet containing 5% L. lepideus fruiting bodies reduced plasma total cholesterol, triglyceride, low-density lipoprotein, total lipid, phospholipids, and the ratio of low-density to high-density lipoprotein. Body weight was reduced. The diet did not adversely affect plasma biochemical and enzyme profiles. L. lepideus reduced significantly plasma beta- and pre-beta-lipoprotein, while alpha-lipoprotein content was increased. A histological study of hepatic cells by conventional hematoxylin-eosin and oil red O staining revealed normal findings for mushroom-fed hypercholesterolemic rats. The present study suggests that a diet supplemented with L. lepideus can provide health benefits by acting on the atherogenic lipid profile in hypercholesterolemic rats.
Agaricales
;
Animals
;
Azo Compounds
;
Body Weight
;
Cholesterol
;
Diet
;
Electrophoresis, Agar Gel
;
Feces
;
Female
;
Fruit
;
Hepatocytes
;
Humans
;
Insurance Benefits
;
Korea
;
Lentinula
;
Lipoproteins
;
Liver
;
Phospholipids
;
Plasma
;
Rats
3.Idiopathic Retroperitoneal Fibrosis Associated with a Horseshoe Kidney.
Pyung Kyun PARK ; Sung Bong PYO ; An Doc JUNG ; Ji Min JEONG ; Dae Hun LIM ; Joon Suk CHOI ; Hyung Chul LEE ; Kyung Jin OH ; Jin Woong KIM ; Nam Ho KIM
Korean Journal of Nephrology 2010;29(3):376-380
A case of a 52-year-old man with retroperitoneal fibrosis and a horseshoe kidney is presented. Horseshoe kidney is one of the most common renal anomalies and complicated with urinary tract infection, hydronephrosis, calculi, tumor of the renal pelvis, and other multiple congenital abnormalities. Idiopathic retroperitoneal fibrosis is a rare disease characterized by the presence of a retroperitoneal tissue, consisting of chronic inflammation and marked fibrosis, which often entraps ureters or other abdominal organs. The correlation between horseshoe kidney and retroperitoneal fibrosis has not been described. We report a rare case of idiopathic retroperitoneal fibrosis with horseshoe kidney disease demonstrating good response to steroid therapy.
Calculi
;
Congenital Abnormalities
;
Fibrosis
;
Humans
;
Hydronephrosis
;
Inflammation
;
Kidney
;
Kidney Diseases
;
Kidney Pelvis
;
Middle Aged
;
Rare Diseases
;
Retroperitoneal Fibrosis
;
Steroids
;
Ureter
;
Urinary Tract Infections
4.Does Calcineurin Inhibitor Plus Mycophenolate Mofetil Combination Therapy Decrease the Risk of Late Acute Rejection after Liver Transplantation?.
Kwan Woo KIM ; Sung Gyu LEE ; Shin HWANG ; Ki Hun KIM ; Chul Soo AHN ; Deok Bog MOON ; Tae Yong HA ; Gi Won SONG ; Dong Hwan JUNG ; Nam Kyu CHOI ; Jeong Ik PARK ; Gil Chun PARK ; Young Dong YU ; Pyung Jae PARK ; Young Il CHOI
The Journal of the Korean Society for Transplantation 2010;24(2):93-100
BACKGROUND: With advances in immunosuppression, graft and patient survival rates have increased significantly, but acute cellular rejection remains an important problem following liver transplantation (LT), and late acute rejection (LAR) occurs in a small percentage of recipients. Some risk factors for LAR have been identified, yet the cause of LAR has not been completely investigated. The efficacy of mycophenolate mofetil (MMF) administered in combination with calcineurin inhibitor (CNI) for reduction of LAR has been demonstrated. METHODS: Between January 2006 and August 2007, adult LT recipients (n=309) were enrolled in this study. Biopsy-proven acute rejection that occurred >6 months after LT was defined as LAR. The immunosuppression regimens, CNI or CNI plus MMF, were used continuously for at least 6 months after LT. The mean follow-up period was 34.8 months (range, 25~46 months). RESULTS: LAR occurred in 17 cases (5.5%). The incidence of LAR in the CNI (n=138) or CNI plus MMF groups (n=171) was 8.6% (n=12) and 2.9% (n=5), respectively (P=0.015). Multivariate Cox regression confirmed that CNI plus MMF versus CNI therapy is associated with a decreased risk of LAR (relative risk, 0.33; P=0.04). CONCLUSIONS: The incidence of LAR in the CNI plus MMF group was significantly lower than the CNI group. Thus, continuous use of CNI plus MMF may represent a better immunosuppression regimen to decrease the rate of LAR in LT recipients.
Adult
;
Calcineurin
;
Follow-Up Studies
;
Humans
;
Immunosuppression
;
Incidence
;
Liver
;
Liver Transplantation
;
Mycophenolic Acid
;
Rejection (Psychology)
;
Risk Factors
;
Survival Rate
;
Transplants
5.An Open-Label Trial of the 5% Lidocaine Patches for the Treatment of Chronic Pain.
Jee Youn MOON ; Jong Bum CHOI ; Pyung Bok LEE ; He Min SON ; Francis Sanhgun NAM ; Young Chul KIM ; Sang Chul LEE ; Sang Jin LEE
The Korean Journal of Pain 2009;22(3):216-223
BACKGROUND: There have been limited reports on the effectiveness of 5% lidocaine patches (L5Ps) for treating a few types of chronic pain. We utilized L5Ps for chronic pain patients with various diagnoses and who had incompletely responded to their current treatment regimen. This study aimed at describing the results of a retrospective review of an open-label L5P trial to assess L5Ps' effectiveness and safety for treating various chronic pain patients. METHODS: The chronic pain patients with pain lasting longer than 6-month duration were offered a 2-week L5P treatment trial. The patients were maintained on their other analgesic regimens. The treatment effect was measured according to the change from the baseline visual analog scale (VAS) to the week 2 VAS. After a 2-week trial, the patients were asked if they perceived pain improvement with L5Ps by using a four-item Pain Relief Scale (1 = a lot of relief, 2 = slight relief, 3 = no change, 4 = worse pain). RESULTS: In the combined patient population (n = 177), 2-week treatment with the L5Ps significantly improved the week 2 VAS (P = 0.000). Significant improvement in the VAS was reported by the chronic pain patients with postherpetic neuralgia, intercostal neuralgia, degenerative osteoarthritis at knee joint, and other maladies. A higher proportion of the chronic pain patients reported improving their pain by the L5Ps. Seven patients experienced mild or moderate patch-related adverse events. CONCLUSIONS: The L5P provided clinically meaningful pain relief in some refractory chronic pain patients without any severe adverse events.
Chronic Pain
;
Humans
;
Knee Joint
;
Lidocaine
;
Neuralgia
;
Neuralgia, Postherpetic
;
Osteoarthritis
;
Retrospective Studies
6.Renoprotective effect of deflazacort in IgA nephropathy with proteinuria.
Ji Min JEONG ; Dae Hun LIM ; Hyung Chul LEE ; Seul Hyun OH ; Joon Seok CHOI ; Pyung Kyun PARK ; An Doc JUNG ; Jeong Woo PARK ; Eun Hui BAE ; Seong Kwon MA ; Soo Wan KIM ; Nam Ho KIM
Korean Journal of Medicine 2009;77(5):593-600
BACKGROUND/AIMS: Steroid therapy is reported to improve the clinical outcome of IgA nephropathy. In addition, recent studies have revealed that deflazacort has fewer side effects than prednisolone. This study examined the effect of steroids and compared the clinical efficacy of deflazacort and prednisolone in patients with IgA nephropathy. METHODS: We retrospectively reviewed 136 patients with biopsy-proven IgA nephropathy who received deflazacort (n=50), prednisolone (n=29), or neither (n=59), and in whom blood pressure was controlled with angiotensin converting enzyme inhibitors or angiotensin receptor blockers. The mean duration of steroid administration was 9.5+/-9.1 months. The initial clinical status and change in the amount of protein in the 24-hour urine were compared among the three groups. RESULTS: The baseline characteristics (age, blood pressure, serum creatinine level, initial protein in the 24-hour urine, and creatinine clearance) did not differ significantly among the groups. The decrement of protein in the 24-hour urine was higher in the deflazacort and prednisolone groups, as compared with the control group (4.4+/-5.4, 4.2+/-1.5, and 2.1+/-3.1 g/day, respectively, p=0.013). The increment in the creatinine clearance was higher in the deflazacort and prednisolone groups, as compared with the control group (11.5+/-16.4, 12.3+/-26.2, and 4.8+/-14.91.3+/-0.9, respectively, p=0.009). There were no significant differences in the above parameters between the deflazacort and prednisolone groups. CONCLUSIONS: Steroid therapy reduces urinary protein excretion in IgA nephropathy, and the clinical efficacy of deflazacort and prednisolone was found to be similar.
Angiotensin Receptor Antagonists
;
Angiotensin-Converting Enzyme Inhibitors
;
Blood Pressure
;
Creatinine
;
Glomerulonephritis
;
Glomerulonephritis, IGA
;
Humans
;
Immunoglobulin A
;
Prednisolone
;
Pregnenediones
;
Proteinuria
;
Retrospective Studies
;
Steroids
7.Perirenal Lymphangioma Combined With Multiple Splenic and Hepatic Cysts.
Seong Bong PYO ; Dea Hun LIM ; Ji Min JEONG ; An Doc JUNG ; Pyung Kyun PARK ; Min Ho SHIN ; Seung Il JUNG ; Yoo Duk CHOI ; Nam Ho KIM
Korean Journal of Nephrology 2009;28(5):485-489
Lymphangioma usually occurs in children and usually involves neck and axillary region. Renal or perirenal cystic lymphangioma, hepatic lymphangiomatosis and splenic lymphangiomatosis are very rare disorders. Perirenal cystic lymphangioma combined with multiple hepatic cysts or multiple splenic cysts suspected to be lymphangiomatosis has not been reported in adults in this country until now. The patient was a 43-year-old woman who had been diagnosed with multiple splenic cysts about ten years ago. She presented with a perirenal cystic lesion discovered incidentally and we detected small multiple hepatic cysts additionally with abdominal CT. We removed perirenal cyst surgically and a perirenal lymphangioma was confirmed.
Adult
;
Child
;
Female
;
Humans
;
Kidney
;
Liver
;
Lymphangioma
;
Lymphangioma, Cystic
;
Neck
;
Spleen
8.Effect of Splenic Artery Interruption on Complete Blood Count Profiles in Living Donor Liver Transplant Recipients.
Wan Joon KIM ; Deok Bog MOON ; Jeong Ik PARK ; Shin HWANG ; Ki Hun KIM ; Chul Soo AHN ; Tae Yong HA ; Gi Won SONG ; Dong Hwan JUNG ; Kwan Woo KIM ; Nam Kyu CHOI ; Gil Chun PARK ; Young Dong YU ; Pyung Jae PARK ; Young Il CHOI ; Kun Moo CHOI ; Sung Gyu LEE
Korean Journal of Hepato-Biliary-Pancreatic Surgery 2009;13(4):242-250
PURPOSE: Splenectomy during living donor liver transplantation (LDLT) in a hepatitis C virus (HCV)-related cirrhotic recipient was performed by a Tokyo group to enhance the patient's tolerability to post-operative anti-viral treatment by improving complete blood count (CBC) profiles. At our institution, interruption of the splenic artery (SPA) by ligation or embolization in lieu of splenectomy, has been performed in LDLT to modulate portal blood flow in small-for-size graft LDLT or to prevent rupture of SPA aneurysms in recipients. We aimed to determine if interruption of the SPA can serve as an alternative management to splenectomy in LDLT recipients based on our data. METHODS: Patients were classified into the splenic artery ligation group (SAL; n=26) and splenic artery embolization group (SAE; n=19), respectively. Among the recipients without SPA interruption, age-, gender-, and severity of cirrhosis-matched 25 recipients were selected as a control group. Post-operative CBC profiles and spleen size were reviewed retrospectively and compared between the groups. RESULTS: After SAL, platelet and neutrophil counts were significantly increased at 3 and 6 months, and at 1 week and 1 month, respectively (p<0.05). After SAE, platelet and neutrophil counts were significantly increased at 3 and 6 months, and at 1 week and 3 months, respectively. There were no significant complications related to interruption of the SPA. CONCLUSION: Interruption of the SPA may have a role in improving neutrophil and platelet counts in LDLT recipients with severe pancytopenia or in whom antiviral treatment for HCV in anticipated.
Aneurysm
;
Blood Cell Count
;
Blood Platelets
;
Hepacivirus
;
Humans
;
Ligation
;
Liver
;
Liver Transplantation
;
Living Donors
;
Neutrophils
;
Pancytopenia
;
Platelet Count
;
Retrospective Studies
;
Rupture
;
Spleen
;
Splenectomy
;
Splenic Artery
;
Tokyo
;
Transplants
9.Effect of Splenic Artery Interruption on Complete Blood Count Profiles in Living Donor Liver Transplant Recipients.
Wan Joon KIM ; Deok Bog MOON ; Jeong Ik PARK ; Shin HWANG ; Ki Hun KIM ; Chul Soo AHN ; Tae Yong HA ; Gi Won SONG ; Dong Hwan JUNG ; Kwan Woo KIM ; Nam Kyu CHOI ; Gil Chun PARK ; Young Dong YU ; Pyung Jae PARK ; Young Il CHOI ; Kun Moo CHOI ; Sung Gyu LEE
Korean Journal of Hepato-Biliary-Pancreatic Surgery 2009;13(4):242-250
PURPOSE: Splenectomy during living donor liver transplantation (LDLT) in a hepatitis C virus (HCV)-related cirrhotic recipient was performed by a Tokyo group to enhance the patient's tolerability to post-operative anti-viral treatment by improving complete blood count (CBC) profiles. At our institution, interruption of the splenic artery (SPA) by ligation or embolization in lieu of splenectomy, has been performed in LDLT to modulate portal blood flow in small-for-size graft LDLT or to prevent rupture of SPA aneurysms in recipients. We aimed to determine if interruption of the SPA can serve as an alternative management to splenectomy in LDLT recipients based on our data. METHODS: Patients were classified into the splenic artery ligation group (SAL; n=26) and splenic artery embolization group (SAE; n=19), respectively. Among the recipients without SPA interruption, age-, gender-, and severity of cirrhosis-matched 25 recipients were selected as a control group. Post-operative CBC profiles and spleen size were reviewed retrospectively and compared between the groups. RESULTS: After SAL, platelet and neutrophil counts were significantly increased at 3 and 6 months, and at 1 week and 1 month, respectively (p<0.05). After SAE, platelet and neutrophil counts were significantly increased at 3 and 6 months, and at 1 week and 3 months, respectively. There were no significant complications related to interruption of the SPA. CONCLUSION: Interruption of the SPA may have a role in improving neutrophil and platelet counts in LDLT recipients with severe pancytopenia or in whom antiviral treatment for HCV in anticipated.
Aneurysm
;
Blood Cell Count
;
Blood Platelets
;
Hepacivirus
;
Humans
;
Ligation
;
Liver
;
Liver Transplantation
;
Living Donors
;
Neutrophils
;
Pancytopenia
;
Platelet Count
;
Retrospective Studies
;
Rupture
;
Spleen
;
Splenectomy
;
Splenic Artery
;
Tokyo
;
Transplants
10.Effectiveness of Plasmapheresis as a Liver Support for Graft Dysfunction Following Adult Living Donor Liver Transplantation.
Shin HWANG ; Seog Woon KWON ; Gil Chun PARK ; Young Dong YU ; Kwan Woo KIM ; Nam Kyu CHOI ; Young Il CHOI ; Pyung Jae PARK ; Geum Borae PARK ; Dong Hwan JUNG ; Gi Won SONG ; Deok Bog MOON ; Chul Soo AHN ; Ki Hun KIM ; Tae Yong HA ; YuSun MIN ; Suk Kyung HONG ; Kyu Hyouck KYOUNG ; Jeong Ik PARK ; Sung Gyu LEE
The Journal of the Korean Society for Transplantation 2009;23(3):244-251
BACKGROUND: Severe graft dysfunction has been occasionally encountered following adult living donor liver transplantation (LDLT). This study intended to assess the effectiveness of plasmapheresis (PP) as a liver supportive measure in LDLT recipients showing severe graft dysfunction. METHODS: During 1 year of 2007, 276 adult LDLTs were performed in our institution. Of them 27 underwent PP therapy as a liver support. RESULTS: Seventeen underwent PP during the first month following LDLT and another 10 underwent PP after that period. The underlying causes of such liver support were acute and chronic rejections, ischemic damage, viral hepatitis recurrence and unknown causes. A total of 329 sessions of PP were performed for these 27 patients, indicating 12.2+/-9.9 times per patient for 28.1+/-32.2 days. Concurrent hemodiafiltration was done in 66.7%. Serum total bilirubin level was significantly reduced following PP therapy: 23.2+/-6.5 mg/dL before PP and 14.4+/-5.6 mg/dL at 1 week after completion of PP (P<0.001). Other biochemical parameters did not significantly affected by PP. Overall 1-year patient survival rate was 63.0%. Six-month graft survival rate after completion of PP was 82.6% in 17 patients undergoing PP during the first posttransplant month and 30% in 10 patients undergoing PP after 1 month (P= 0.013). CONCLUSIONS: The results of this study implicate that PP has a beneficial effect on the recovery of liver graft function, especially during the early posttransplant period. We suggest to perform active application of PP therapy for liver recipients showing severe graft dysfunction of total bilirubin greater than 15~20 mg/dL.
Adult
;
Bilirubin
;
Graft Survival
;
Hemodiafiltration
;
Hepatitis
;
Humans
;
Liver
;
Liver Transplantation
;
Living Donors
;
Plasmapheresis
;
Recurrence
;
Rejection (Psychology)
;
Survival Rate
;
Transplants

Result Analysis
Print
Save
E-mail